Authors

Latest:

Dr. O'Neil on Neuroendocrine Tumors

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).

Bertram Yuh, MD

Latest:

Dr Yuh on the Role of Genetic Factors in Risk Stratification for Prostate Cancer

Bertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.

Bertrand Tombal, MD, PhD, Cliniques Universitaires Saint-Luc

Latest:

Dr Tombal on the Pharmacokinetics of Darolutamide Plus Docetaxel in mHSPC

Bertrand Tombal, MD, PhD, discusses the pharmacokinetics of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer.

Beth DuPree, MD

Latest:

Dr. DuPree Provides Z11 Trial Takeaway Points

Dr. Beth DuPree from Holy Redeemer Health System Provides Z11 Trial Takeaway Points

Beth Eaby-Sandy, CRNP, OCN, University of Pennsylvania

Beth Fand Incollingo

Latest:

Sotorasib Shows Encouraging Antitumor Activity in Advanced NSCLC

The investigational drug sotorasib demonstrated promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation, an aberration for which no targeted treatment has yet been approved.

Beth Gilbert

Latest:

Essential Components of Survivorship Care

At the 2012 NCCN annual meeting, a panel of oncology nurses discussed the essential components of healthcare for survivors, challenges survivors face, and survivorship program models.

Beth Incollingo

Latest:

Genes Predispose Some Anthracycline Patients to Heart Failure

Researchers have identified a genetic profile of the patients who are most likely to develop congestive heart failure after being treated with anthracyclines and then undergoing hematopoeitic stem cell transplant (HCT) for a range of blood cancers.

Beth Overmoyer, MD

Latest:

Dr. Overmoyer on Inflammatory Triple-Negative Breast Cancer

Beth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.

Beth Y. Karlan MD

Latest:

Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer

Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Bethany Anderson, MD

Latest:

MRI-Guided Radiation Therapy Modernizes Breast Conservation Methods

The major advance of the MRI-guided radiotherapy system is the ability to visualize the lumpectomy cavity before and during the delivery of each treatment.

Betsy O'Donnell, MD

Latest:

Cancer Screening and Management: Overview of the Current Landscape

A panel of esteemed cancer experts explore the challenges and opportunities in cancer screening and identification, shedding light on the evolving landscape and its impact on clinical practice.

Betty Hamilton, MD

Latest:

Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AML

Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.

Bharat Patel, MBA

Latest:

Adequate Resources Are Key to Oncology Clinical Trial Success

With all the exciting developments occurring in cancer research, community oncology practices that currently do not offer clinical trials to patients may be considering executing a research program.

Bhavana Pothuri, MD

Latest:

Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR Agents

Panelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.

Bianca D. Santomasso, MD, PhD

Latest:

Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell Lymphoma

Bianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.

Bijal D. Shah, MD

Latest:

Future Directions and Unmet Needs in Relapsed/Refractory MCL

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Bijal D. Shah, MD, Anthony S. Stein, MD, Gehr Family Center for Leukemia Research

Bijal D. Shah, MD, H. Lee Moffitt Cancer Center & Research Institute

Bijal D. Shah, MD, Moffitt Cancer Center